Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

EAACI Position Paper: Hypersensitivity reactions to chemotherapy.

15 Feb, 2022 | 09:54h | UTC

Hypersensitivity reactions to chemotherapy: an EAACI Position Paper – Allergy

 

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant.

13 Feb, 2022 | 22:49h | UTC

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant – STAT

Related:

FDA halts use of antibody drugs that don’t work vs. Omicron.

Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

 

Systematic Review: Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations.

9 Feb, 2022 | 10:02h | UTC

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review – Clinical Microbiology and Infection

 

Cannabis-related allergies: an international overview and consensus recommendations.

9 Feb, 2022 | 08:18h | UTC

Cannabis-related allergies: an international overview and consensus recommendations – Allergy

 

Perspective | Three, four or more: what’s the magic number for booster shots?

8 Feb, 2022 | 10:03h | UTC

Three, four or more: what’s the magic number for booster shots? – Nature

 

Where did Omicron come from? Three key theories.

8 Feb, 2022 | 10:04h | UTC

Where did Omicron come from? Three key theories – Nature

 

Wilderness Medical Society Clinical Practice Guidelines on Anaphylaxis.

7 Feb, 2022 | 08:41h | UTC

Wilderness Medical Society Clinical Practice Guidelines on Anaphylaxis – Wilderness and Environmental Medicine

Related Guidelines:

Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update

Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2019 Update

Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Heat Illness: 2019 Update

Wilderness Medical Society Clinical Practice Guidelines for the Out-of-Hospital Evaluation and Treatment of Accidental Hypothermia: 2019 Update

Wilderness Medical Society Clinical Practice Guidelines for the Treatment and Prevention of Drowning: 2019 Update

Wilderness Medical Society Clinical Practice Guidelines for Spinal Cord Protection

Wilderness Medical Society Clinical Practice Guidelines for Water Disinfection for Wilderness, International Travel, and Austere Situations

Wilderness Medical Society Clinical Practice Guidelines for Diabetes Management

 

Therapies for Olfactory Dysfunction — an Update.

7 Feb, 2022 | 08:29h | UTC

Therapies for Olfactory Dysfunction — an Update – Current Allergy and Asthma Reports (if the link is paywalled, try this one)

 

What the Omicron wave is revealing about human immunity.

4 Feb, 2022 | 10:01h | UTC

What the Omicron wave is revealing about human immunity – Nature

 

Anaphylaxis: Highlights from the practice parameter update.

4 Feb, 2022 | 08:43h | UTC

Anaphylaxis: Highlights from the practice parameter update – Cleveland Clinic Journal of Medicine

Original Article: Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis – Journal of Allergy and Clinical Immunology

 

Short Review | Hypersensitivity reactions to vaccines in children: from measles to SARS-CoV-2.

2 Feb, 2022 | 08:13h | UTC

Hypersensitivity reactions to vaccines in children: from measles to SARS-CoV-2 – Pediatric Allergy and Immunology

Commentary: Vaccine hypersensitivity in children – News Medical

 

Review: Eosinophils and eosinophilic immune dysfunction in health and disease.

2 Feb, 2022 | 08:15h | UTC

Eosinophils and eosinophilic immune dysfunction in health and disease – European Respiratory Review

 

FDA halts use of antibody drugs that don’t work vs. Omicron.

30 Jan, 2022 | 14:35h | UTC

FDA halts use of antibody drugs that don’t work vs. omicron – Associated Press

Related: Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

 

RCT: Vitamin D supplementation for older adults (mean age 67 years) for 5 years reduced the risk of autoimmune diseases by 22%. Absolute risk in the treatment group was 0.95% vs. 1.19% in the placebo group.

30 Jan, 2022 | 14:30h | UTC

Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial – The BMJ

Commentary: Vitamin D and fish oil supplements may help prevent autoimmune disease, study says – CNN

Related:

RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.

RCT: Vitamin D supplementation is not beneficial for the prevention of cardiovascular disease and cancer.

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

USPSTF Statement: Insufficient evidence to recommend Vitamin D deficiency screening

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

 

Guideline Summary: Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

30 Jan, 2022 | 14:11h | UTC

Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy – JCO Oncology Practice

Original Article: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

Related:

Clinical practice guideline on immune checkpoint inhibitor-related adverse events.

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)

 

RCT: Hyperimmune immunoglobulin did not improve outcomes in hospitalized patients with COVID-19.

28 Jan, 2022 | 08:42h | UTC

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial – The Lancet

Commentaries:

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 – The Lancet

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 – NIH News Releases

 

Perspective: Will Omicron leave most of us immune?

28 Jan, 2022 | 08:34h | UTC

Will Omicron Leave Most of Us Immune? – The Atlantic

 

Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

27 Jan, 2022 | 10:03h | UTC

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant – New England Journal of Medicine

Commentary: Current anti-COVID pills work well against omicron, but antibody drugs are less effective, study finds – University of Wisconsin-Madison

 

Commentary on Twitter

 

Review | Immune-checkpoint inhibitors: long-term implications of toxicity.

27 Jan, 2022 | 09:39h | UTC

Immune-checkpoint inhibitors: long-term implications of toxicity – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)

 

Commentary on Twitter

 

Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach.

27 Jan, 2022 | 09:18h | UTC

Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach – Swiss Medical Weekly

 

ACP living, rapid review: risk for reinfection after SARS-CoV-2.

25 Jan, 2022 | 09:47h | UTC

Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection – Annals of Internal Medicine

 

Commentary on Twitter

 

Case-control study: 3 doses of mRNA vaccines were associated with reduced infections with SARS-CoV-2 Omicron and Delta variants compared to no vaccination or 2 doses.

24 Jan, 2022 | 08:56h | UTC

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants – JAMA

Editorial: Booster Vaccination to Prevent COVID-19 in the Era of Omicron: An Effective Part of a Layered Public Health Approach – JAMA

Commentaries: New data show booster doses protect against Omicron – CIDRAP

Boosters provide the best protection against Omicron variant, CDC studies show, raising new questions about what it means to be fully vaccinated – CNN

Related CDC Studies:

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 – CDC Morbidity and Mortality Weekly Report

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 – CDC Morbidity and Mortality Weekly Report

 

Commentary on Twitter

 

A guide to immunotherapy for COVID-19.

24 Jan, 2022 | 08:29h | UTC

A guide to immunotherapy for COVID-19 – Nature Medicine

 

SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses.

24 Jan, 2022 | 08:26h | UTC

SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses – Cell

News Release: Breakthrough infections spur strong antibody responses – University of Washington School of Medicine

 

RCT: In children with peanut allergy, initiation of peanut oral immunotherapy before age 4 years induced desensitization in 71% of patients and remission in 21%.

24 Jan, 2022 | 08:18h | UTC

Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study – The Lancet (link to abstract – $ for full-text)

News Release: Oral immunotherapy induces remission of peanut allergy in some young children – NIH News Releases

Commentary: Peanut Oral Immunotherapy at Younger Age Ups Desensitization in Children – HealthDay

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.